All In Biotech

Drug Trial Radar · NCT00940550

Study to Investigate the Effects of Melatonin, Temazepam & Zolpidem on Sleep EEG in Men and Women

A Randomised, Double-Blind, Placebo-Controlled Four-Way Cross-Over Trial to Study the Effects of Prolonged-Release Melatonin, Temazepam and Zolpidem on the Spectral Composition of the EEG During Nocturnal Sleep in Healthy Middle-Aged Men and Women

Last checked: Nov 20, 2026Latest source record: Aug 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jul 2009

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
University of SurreyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
H. Lundbeck A/S
First posted
Jul 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 55 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study has been designed to compare the effects of melatonin with those of drugs (temazepam and zolpidem) regularly prescribed for the treatment of insomnia, in healthy, middle-aged volunteers. The study will take place at one centre. Volunteers consenting to participate in the study will have their eligibility confirmed by a screening panel, including spending one night in the sleep clinic to acclimatize to the study procedures. Blood and urine samples will be collected during this overnight visit. Volunteers continuing to remain eligible will receive, in turn, melatonin, temazepam, zolpidem and placebo as a single dose during 4 treatment phases lasting one night and separated by at least five days. Neither the volunteer nor the study staff will be aware of which drug each volunteer is receiving at each treatment phase. The volunteer's electrical brain activity will be measured whilst sleeping. Other aspects of sleep, including measures of sleep quality, will also be measured. Urine samples will be collected during each treatment phase. Volunteers will undergo an assessment of health prior to departure from the clinic at their last treatment phase, and study staff will telephone 2 weeks later to obtain further information on their health status. The primary study objective is to compare EEG power spectra during nonREM sleep in the slow-wave frequencies following administration with melatonin to temazepam.

Conditions

  • Insomnia

Interventions

  • Prolonged-release melatoninDrug

    2 mg tablet, once.

  • TemazepamDrug

    20 mg capsule, once

  • ZolpidemDrug

    10 mg capsule, once

  • Placebo to match melatonin, zolpidem and temazepamDrug

    Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EEG Power density in slow wave frequencies during NREM sleepTime frame: Treatment Periods 1 to 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Surrey CRC, University of Surrey, Egerton Road

    Guildford, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.